Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells

Jing Li, Meixiang Xu, Zhen Yang, Albert Li, Jianli Dong

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Deregulation of RAS-RAF-MEK-ERK and p16INK4A-cycylin D:CDK4/6-RB pathways is important for melanoma development. Chemotherapeutic agents targeting both pathways were developed but results of clinical studies with monotherapies were disappointing. We examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment. The apoptosis was associated with downregulation of BCL2, BCL2L1, BIRC5, and upregulation of BIM. Our results indicate that simultaneously targeting ERK and RB pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.

Original languageEnglish (US)
Pages (from-to)350-356
Number of pages7
JournalCancer Investigation
Volume28
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Melanoma
Apoptosis
MAP Kinase Signaling System
Up-Regulation
Down-Regulation
Cell Line

Keywords

  • Apoptosis
  • CDK4 inhibitor
  • MEK inhibitor
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. / Li, Jing; Xu, Meixiang; Yang, Zhen; Li, Albert; Dong, Jianli.

In: Cancer Investigation, Vol. 28, No. 4, 04.2010, p. 350-356.

Research output: Contribution to journalArticle

Li, Jing ; Xu, Meixiang ; Yang, Zhen ; Li, Albert ; Dong, Jianli. / Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. In: Cancer Investigation. 2010 ; Vol. 28, No. 4. pp. 350-356.
@article{5a041c28737246508973c2d47718f6d9,
title = "Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells",
abstract = "Deregulation of RAS-RAF-MEK-ERK and p16INK4A-cycylin D:CDK4/6-RB pathways is important for melanoma development. Chemotherapeutic agents targeting both pathways were developed but results of clinical studies with monotherapies were disappointing. We examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment. The apoptosis was associated with downregulation of BCL2, BCL2L1, BIRC5, and upregulation of BIM. Our results indicate that simultaneously targeting ERK and RB pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.",
keywords = "Apoptosis, CDK4 inhibitor, MEK inhibitor, Melanoma",
author = "Jing Li and Meixiang Xu and Zhen Yang and Albert Li and Jianli Dong",
year = "2010",
month = "4",
doi = "10.3109/07357900903286966",
language = "English (US)",
volume = "28",
pages = "350--356",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells

AU - Li, Jing

AU - Xu, Meixiang

AU - Yang, Zhen

AU - Li, Albert

AU - Dong, Jianli

PY - 2010/4

Y1 - 2010/4

N2 - Deregulation of RAS-RAF-MEK-ERK and p16INK4A-cycylin D:CDK4/6-RB pathways is important for melanoma development. Chemotherapeutic agents targeting both pathways were developed but results of clinical studies with monotherapies were disappointing. We examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment. The apoptosis was associated with downregulation of BCL2, BCL2L1, BIRC5, and upregulation of BIM. Our results indicate that simultaneously targeting ERK and RB pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.

AB - Deregulation of RAS-RAF-MEK-ERK and p16INK4A-cycylin D:CDK4/6-RB pathways is important for melanoma development. Chemotherapeutic agents targeting both pathways were developed but results of clinical studies with monotherapies were disappointing. We examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment. The apoptosis was associated with downregulation of BCL2, BCL2L1, BIRC5, and upregulation of BIM. Our results indicate that simultaneously targeting ERK and RB pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.

KW - Apoptosis

KW - CDK4 inhibitor

KW - MEK inhibitor

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=77950557554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950557554&partnerID=8YFLogxK

U2 - 10.3109/07357900903286966

DO - 10.3109/07357900903286966

M3 - Article

VL - 28

SP - 350

EP - 356

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 4

ER -